- Home
- TXNM vs SRRK Comparison
TXNM vs SRRK Comparison
Compare TXNM & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXNM
- SRRK
- Stock Information
- Founded
- TXNM 1917
- SRRK 2012
- Country
- TXNM United States
- SRRK United States
- Employees
- TXNM N/A
- SRRK N/A
- Industry
- TXNM
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TXNM
- SRRK Health Care
- Exchange
- TXNM NYSE
- SRRK Nasdaq
- Market Cap
- TXNM 4.4B
- SRRK 4.2B
- IPO Year
- TXNM N/A
- SRRK 2018
- Fundamental
- Price
- TXNM $48.46
- SRRK $43.12
- Analyst Decision
- TXNM Buy
- SRRK Strong Buy
- Analyst Count
- TXNM 5
- SRRK 7
- Target Price
- TXNM $52.00
- SRRK $40.43
- AVG Volume (30 Days)
- TXNM 814.0K
- SRRK 1.1M
- Earning Date
- TXNM 02-04-2025
- SRRK 11-12-2024
- Dividend Yield
- TXNM 3.20%
- SRRK N/A
- EPS Growth
- TXNM 10.09
- SRRK N/A
- EPS
- TXNM 1.97
- SRRK N/A
- Revenue
- TXNM $1,906,349,000.00
- SRRK N/A
- Revenue This Year
- TXNM $11.70
- SRRK N/A
- Revenue Next Year
- TXNM $4.52
- SRRK N/A
- P/E Ratio
- TXNM $24.64
- SRRK N/A
- Revenue Growth
- TXNM N/A
- SRRK N/A
- 52 Week Low
- TXNM $34.63
- SRRK $6.76
- 52 Week High
- TXNM $50.28
- SRRK $46.19
- Technical
- Relative Strength Index (RSI)
- TXNM 53.70
- SRRK 57.37
- Support Level
- TXNM $45.71
- SRRK $38.72
- Resistance Level
- TXNM $49.60
- SRRK $45.15
- Average True Range (ATR)
- TXNM 1.01
- SRRK 2.33
- MACD
- TXNM 0.01
- SRRK -0.32
- Stochastic Oscillator
- TXNM 70.69
- SRRK 73.28
About TXNM TXNM ENERGY INC
TXNM Energy Inc is a holding company that owns regulated utility companies providing energy to houses and businesses across Texas and New Mexico using its utilities.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.